Immunomodulation by a TLR4-interacting surfactant protein-A peptide

Shanjana Awasthi Ph.D.

Principal Investigator

Agency: OU Growth Fund


Dr. Awasthi has identified a lead candidate SPA4 peptide with immunomodulatory properties. Results from in silico, cell culture and animal models reveal that the SPA4 peptide binds to TLR4, enhances phagocytosis, suppresses inflammatory response and alleviates clinical symptoms. Immediate application of this peptide could be in modifying the currently available clinical surfactants approved for the treatment of respiratory distress syndrom in infants. A comprehensive evaluation in models of infections, inflammation and inflammation-induced cancer (where TLR4 is involved) will establish its therapeutic potential.